Dysregulated Renin-Angiotensin-Aldosterone System Contributes to Pulmonary Arterial Hypertension

被引：271

作者：

de Man, Frances S. ^{[1
,2
,3
,4
]}

Tu, Ly ^{[3
,4
]}

Handoko, M. Louis ^{[1
,2
]}

Rain, Silvia ^{[1
]}

Ruiter, Gerrina ^{[1
]}

Francois, Charlene ^{[3
,4
]}

Schalij, Ingrid ^{[1
]}

Dorfmueller, Peter ^{[3
,4
]}

Simonneau, Gerald ^{[3
,4
,5
]}

Fadel, Elie ^{[3
,4
]}

Perros, Frederic ^{[3
,4
]}

Boonstra, Anco ^{[1
]}

Postmus, Piet E. ^{[1
]}

van der Velden, Iolanda ^{[2
]}

Vonk-Noordegraaf, Anton ^{[1
]}

Humbert, Marc ^{[3
,4
,5
]}

Eddahibi, Saadia ^{[3
,4
]}

Guignabert, Christophe ^{[3
,4
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Pulmonol, Inst Cardiovasc Res, NL-1081 HV Amsterdam, Netherlands

[2] Vrije Univ Amsterdam, Med Ctr, Dept Physiol, Inst Cardiovasc Res, NL-1081 HV Amsterdam, Netherlands

[3] Ctr Chirurg Marie Lannelongue, LERMIT, LabEx, INSERM,UMR 999, Le Plessis Robinson, France

[4] Univ Paris 11, Sch Med, Le Kremlin Bicetre, France

[5] Hop Bicetre, AP HP, Ctr Reference Hypertens Pulm Severe, Serv Pneumol,DHU Thorax Innovat, Le Kremlin Bicetre, France

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2012年 / 186卷 / 08期

关键词：

idiopathic pulmonary arterial hypertension; renin angiotensin system; endothelial cells; smooth muscle cells; monocrotaline; RIGHT HEART-FAILURE; CONVERTING ENZYME; CAPTOPRIL; SURVIVAL; PROGRESSION; ACTIVATION; EXPRESSION; PREVENTION; PHYSIOLOGY; LOSARTAN;

D O I：

10.1164/rccm.201203-0411OC

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Rationale: Patients with idiopathic pulmonary arterial hypertension (iPAH) often have a low cardiac output. To compensate, neurohormonal systems such as the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system are up-regulated, but this may have long-term negative effects on the progression of iPAH. Objectives: Assess systemic and pulmonary RAAS activity in patients with iPAH and determine the efficacy of chronic RAAS inhibition in experimental PAH. Methods: We collected 79 blood samples from 58 patients with iPAH in the VU University Medical Center Amsterdam (between 2004 and 2010) to determine systemic RAAS activity. Measurements and Main Results: We observed increased levels of renin, angiotensin (Ang)I, and AngII, which were associated with disease progression (P < 0.05) and mortality (P < 0.05). To determine pulmonary RAAS activity, lung specimens were obtained from patients with iPAH (during lung transplantation, n = 13) and control subjects (during lobectomy or pneumonectomy for cancer, n = 14). Local RAAS activity in pulmonary arteries of patients with iPAH was increased, demonstrated by elevated angiotensin-converting enzyme activity in pulmonary endothelial cells and increased AngII type 1 (AT(1)) receptor expression and signaling. In addition, local RAAS up-regulation was associated with increased pulmonary artery smooth muscle cell proliferation via enhanced AT(1) receptor signaling in patients with iPAH compared with control subjects. Finally, to determine the therapeutic potential of RAAS activity, we assessed the chronic effects of an AT(1) receptor antagonist (losartan) in the monocrotaline PAH rat model (60 mg/kg). Losartan delayed disease progression, decreased right ventricular afterload and pulmonary vascular remodeling, and restored right ventricular-arterial coupling in rats with PAH. Conclusions: Systemic and pulmonary RAAS activities are increased in patients with iPAH and are associated with increased pulmonary vascular remodeling. Chronic inhibition of RAAS by losartan is beneficial in experimental PAH.

引用

页码：780 / 789

页数：10

共 39 条

[1] Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics [J].